Package Leaflet: Information for the User
Prometax 4.6mg/24h transdermal patch
Prometax 9.5mg/24h transdermal patch
Prometax 13.3mg/24h transdermal patch
rivastigmine
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the Package Leaflet
The active substance of Prometax is rivastigmine.
Rivastigmine belongs to the group of cholinesterase inhibitors. In patients with Alzheimer's dementia, certain nerve cells die in the brain, causing low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine acts by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Prometax allows the increase of acetylcholine in the brain, helping to reduce the symptoms of Alzheimer's disease.
Prometax is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability, and behavior.
Do not use Prometax
If you are in any of these situations, inform your doctor and do not use Prometax transdermal patches.
Warnings and precautions
Consult your doctor before starting to use Prometax:
If you are in any of these situations, your doctor may consider it necessary to monitor you more closely while you are being treated.
If you have not used the patches for more than three days, do not put on another one without consulting your doctor first.
Children and adolescents
Prometax should not be used in the pediatric population for the treatment of Alzheimer's disease.
Other medications and Prometax
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Prometax may interfere with anticholinergic medications, some of which are medications used to relieve stomach cramps or spasms (e.g., dicyclomine), for the treatment of Parkinson's disease (e.g., amantadine), or to prevent motion sickness (e.g., diphenhydramine, scopolamine, or meclizine).
Prometax transdermal patches should not be administered at the same time as metoclopramide (a medication used to relieve or prevent nausea and vomiting). Taking the two medications together may cause problems such as stiffness in the limbs and hand tremors.
In case you need to undergo surgery while using Prometax transdermal patches, inform your doctor that you are using it, as it may potentiate the effects of some muscle relaxants used in anesthesia.
Caution should be exercised when using Prometax transdermal patches with beta blockers (medications such as atenolol used to treat hypertension, angina, and other heart conditions). Taking the two medications together may cause complications such as a decrease in heart rate (bradycardia) that can lead to fainting or loss of consciousness.
Caution should be exercised when using Prometax with other medications that may affect heart rhythm or the heart's electrical system (QT prolongation).
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant, it is necessary to evaluate the benefits of using Prometax against the possible adverse effects for the fetus. Prometax should not be used during pregnancy unless it is clearly necessary.
You should not breastfeed while being treated with Prometax transdermal patches.
Driving and using machines
Your doctor will inform you if your condition allows you to drive or use machinery safely. Prometax transdermal patches may cause dizziness and severe confusion. If you feel dizzy or confused, do not drive or use machinery, and do not perform other tasks that require your attention.
Follow the instructions for administration of Prometax transdermal patches exactly as indicated by your doctor. If in doubt, consult your doctor, pharmacist, or nurse again.
IMPORTANT:
How to start treatment
Your doctor will indicate the most suitable dose of Prometax transdermal patch for your case.
During treatment, your doctor may adjust the dose depending on your individual needs.
If you have not used the patches for more than three days, do not put on another one without consulting your doctor first. Treatment with the transdermal patch can be restarted at the same dose if treatment is not interrupted for more than three days. Otherwise, your doctor will have you restart your treatment with Prometax 4.6 mg/24 h.
Prometax can be used with food, drink, and alcohol.
Where to apply your Prometax transdermal patch
Every 24 hours, remove the previous patch before applying a NEW patch to ONLY ONE of the following possible areas. |
Each time you change the patch, remove the previous day's patch before applying a new patch to a different area of the skin (e.g., one day on the right side of the body and the next day on the left side; or one day on the upper part of the body and the next day on the lower part). Wait at least 14 days before applying a new patch to the same area of skin again.
How to apply your Prometax transdermal patch
Prometax patches are thin, opaque plastic and stick to the skin. Each patch is in a pouch that protects it until you are ready to apply it. Do not open the pouch or remove the patch until you are ready to apply it.
|
Only open the pouch when you are ready to apply the patch. Cut the pouch along the dotted line with scissors and remove the patch from the pouch. |
|
|
If it helps, you can write on the patch, for example, the day of the week, with a fine-tipped pen. |
You should wear the patch continuously until it is time to change it for a new one. When you apply a new patch, you can try different areas to find the ones that are most comfortable and where clothing does not rub against the patch.
How to remove your Prometax transdermal patch
Gently pull one of the edges of the patch to slowly detach it from the skin. If adhesive residues remain on the skin, soak the area with warm water and mild soap or use baby oil to remove it. Do not use alcohol or other solvents (nail polish removers or other solvents).
After removing the patch, wash your hands with soap and water. If you get the patch in your eyes or if your eyes become red after handling the patch, rinse them immediately with plenty of water and seek medical advice if the symptoms do not resolve.
Can you wear your Prometax transdermal patch while bathing, swimming, or exposing yourself to the sun?
What to do if a patch falls off
If a patch falls off, apply a new one for the rest of that day and change it the next day at the usual time.
When and for how long should you wear your Prometax transdermal patch
If you use more Prometax than you should
If you accidentally apply more than one patch, remove all patches from the skin and inform your doctor. You may need medical attention. Some people who have accidentally taken too high doses of Prometax orally have experienced nausea, vomiting, diarrhea, high blood pressure, and hallucinations. A slowing of the heart rate and fainting may also occur.
If you forget to use Prometax
If you realize you have forgotten to apply a patch, apply it immediately. The next day, apply the next patch at the usual time. Do not apply two patches to make up for the one you forgot.
If you interrupt treatment with Prometax
Inform your doctor or pharmacist if you stop using the patches.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Prometax transdermal patches can cause adverse effects, although not all people will experience them.
You may have adverse effects more frequently when starting your treatment or when your dose is increased. Generally, the adverse effects will slowly disappear as your body gets used to the medicine.
If you notice any of the following adverse effects that may be serious, remove the patch and inform your doctor immediately.
Frequent(may affect up to 1 in 10 people)
Infrequent(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Unknown(cannot be estimated from available data)
If you notice any of the adverse effects listed above, remove the patch and inform your doctor immediately.
Other Adverse Effects Experienced with Prometax Capsules or Oral Solution and that May Occur with Patches:
Frequent(may affect up to 1 in 10 people)
Infrequent(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Prometax Composition
Product Appearance and Package Contents
Thin transdermal patch composed of three layers. The outer layer is beige and marked with:
Each pouch contains one transdermal patch. Patches are available in packages containing 7 or 30 pouches and in multi-packs containing 60 or 90 pouches. Only some package sizes may be marketed.
Marketing Authorization Holder
Almirall, S.A.
Ronda General Mitre, 151
08022 Barcelona
Spain
Manufacturer
LTS Lohmann Therapie-Systeme AG
Lohmannstrasse 2
56626 Andernach
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien, ???????, Ceská republika, Danmark, Deutschland, Eesti, Ελλάδα, España, France, Hrvatska, Ireland, Ísland, Italia, Κύπρος, Latvija, Lietuva, Luxembourg/Luxemburg, Magyarország, Malta, Nederland, Norge, Österreich, Polska, Portugal, România, Slovenija, Slovenská republika, Suomi/Finland, Sverige
Almirall, S.A.
Tel: +34 93 306 42 00
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information about this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu